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sumer PriceHospital Services index.RESULTS: Total chargeswere $9.8; $9.6; and $9.5
billion for 2006, 2007, and2008, respectively. Thehighest total chargeswere associated
with events for which Medicaid was the expected primary payer ($3.3 billion), fol-
lowed by Medicare ($2.2 billion) for each year In 2006, charges were $2.0 billion for
self-paid events, and $1.7 billion for privately insured events; this relationship was
reversed in 2007 and 2008. Adjusted mean per-event charges were $19,413; $19,560;
and $17,690 for 2006, 2007, and 2008, respectively. Compared to events covered by
private insurance, adjusted charges for Medicare- andMedicaid-covered events were
statistically significantlyhigher,while self-paid eventshad significantly lower charges
(p 0.001 for all years). Age, number of comorbidities, presence of cardiac or respira-
tory disease, gastrointestinal hemorrhage, and acute pancreatitis were significantly
positively associated with total charges (p  0.001 for all). CONCLUSIONS: The eco-
nomic burden of opioid abuse on the healthcare system is substantial and associated
charges are related to insurance status. Factors associated with charges for events
related to opioid abuse ormisuse were also identified, resulting in better understand-
ing of costs of opioid abuse andmisuse.
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ANTIDEPRESSANT TREATMENT PATTERNS, HEALTH CARE UTILIZATION AND
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This study evaluated treatment patterns, health care resource utilization, and cost associated
with the use of escitalopram, duloxetine, venlafaxine and desvenlafaxine for MDD.
OBJECTIVES: To assess total and disease-related healthcare costs among patients
diagnosedwithMDD.METHODS: This retrospective cohort study used administra-
tive claims from a large health plan. Patients aged 18-64 with 1medical claim for
MDD and  1 pharmacy claim for branded formulations of escitalopram, dulox-
etine, venlafaxine or desvenlafaxine were identified between January 1, 2009 and
November 30, 2009. Patients were excluded if they had a claim for bipolar disorder
or were not continuously enrolled during the study period. Proportion of days
covered (PDC), healthcare utilization and cost were assessed using descriptive sta-
tistics. Generalized linear model (GLM) with the log link function and a gamma
distribution were also used to examine the association between healthcare cost
while controlling for demographic and clinical characteristics. RESULTS: A total of
45,913 patients were identified. Almost half initiated on escitalopram (47%), with
the remaining patients on duloxetine, 25%, venlafaxine, 21%, and desvenlafaxine,
7%. MDD-specific health care cost was lowest for desvenlafaxine ($1948) followed
by escitalopram ($2065), duloxetine ($2867), and venlafaxine ($3078). Likewise, total
cost of care was lowest for desvenlafaxine ($11,480), followed by escitalopram
($11,879), venlafaxine ($13,380) and duloxetine ($16,384). Analyses that controlled
for variables including age, gender, region, pre-index total all cause-related health
care costs, PDC and used desvenlafaxine as reference group, indicated a significant
difference in MDD-related cost (duloxetine: cost ratio (CR)1.270, venlafaxine:
CR1.388, p0.0001 for both; escitalopram: CR0.986, p0.3994) and total cost (du-
loxetine: CR1.139, venlafaxine: CR1.051, p0.05 for both; escitalopram:
CR0.946, p0.0017). CONCLUSIONS: In this population, there appears to be an
association between use of desvenlafaxine and lower post-index MDD specific and
total cost of care, compared to duloxetine and venlafaxine. There may be unob-
servable factors that were not accounted for influencing these results.
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OBJECTIVES: To describe the demographics, prescription drug utilization, medica-
tion adherence, and pharmacy costs for Medicare Advantage and Medicare Pre-
scription Drug Plan members initiated on paliperidone palmitate (PALI-PALM), a
long-acting antipsychotic for treating schizophrenia. METHODS: The Humana
pharmacy claims database was used to identify Medicare Advantage andMedicare
Prescription Drug Plan members with a pharmacy claim for PALI-PALM between
September 1, 2009, and December 31, 2010. Six-month preindex and postindex
observation periods were used to assess medication utilization and medication-
related costs for patients starting PALI-PALM.Medication possession ratio (MPR) for
PALI-PALMwas calculated using a fixed denominator of sixmonths.RESULTS: Four
hundred forty-one patients met the inclusion criteria. Mean (SD) age was 46.9
(12.6) years. Three hundred ninety-seven patients (90.0%) had a low-income sub-
sidy (LIS), and 331 (75.1%) were dually eligible for Medicaid. Patients initiated on
PALI-PALM received amean of 1.9 (1.0) unique antipsychotics during the preindex
period. One hundred six patients (24%) who had initiated on PALI-PALM had re-
ceived 3 or more antipsychotics during the preindex period. Antidepressant
(56.9%), anticonvulsant (49.2%), and antiparkinsonism (39.0%) drugs were themost
frequently observed nonantipsychotic mental health medications during the pre-
index period. Compared with the preindex period, use of benzodiazepines and
nonbenzodiazepine anxiolytics decreased during the postindex period (benzodiaz-
epines: 10.0% versus 7.3%; McNemar’s test, p0.034; nonbenzodiazepine anxiolyt-
ics: 12.5% versus 8.4%; McNemar’s test, p0.007). Two hundred forty-one patients
(54.6%) displayed an MPR for PALI-PALM 0.80 during the 6-month postindex pe-
riod. Analysis regarding medication-related costs will be presented in the poster.
CONCLUSIONS: Amajority of Medicare members who had initiated on PALI-PALM
had a LIS and dual eligibility. Use of multiple antipsychotics during the preindex
period was common among members initiated on PALI-PALM. We observed a re-
duction in the use of benzodiazepines and nonbenzodiazepine anxiolytics among
members receiving PALI-PALM.
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OBJECTIVES: Guanfacine is a centrally-acting alpha-2 adrenoceptor agonist avail-
able in immediate (GIR) and extended release (GXR) formulations. GIR is FDA-
approved for hypertension, but is prescribed off-label for ADHD. GXR is US ap-
proved for symptomatic treatment of pediatric ADHD as mono- or adjunctive
therapy. No outcomes study has compared the two formulations. This study de-
scriptively compares treatment patterns, resource utilization, and cost, between
children and adolescents with ADHD initiating treatment with GIR versus GXR.
METHODS: Patients, aged 6-17, with  1 claim for GIR or GXR from November 1,
2009-December 30, 2010 were identified from a large US commercial medical and
pharmacy claims database. Patients had  1 primary diagnosis of ADHD (ICD-9
codes: 314.00, 314.01) during the baseline period, no prior guanfacine use or hyper-
tension diagnosis, and continuous eligibility for 6-months pre- and post-guanfa-
cine initiation. Patient characteristics, resource utilization and costs were descrip-
tively compared using Chi-square and student t-tests. Treatment patterns were
compared using Log-rank test. RESULTS: The GIR and GXR cohorts included 743
and 2,344 patients, respectively. At baseline, patients initiating GIR had signifi-
cantly more adjunctive therapy use (59.1% versus 54.6%, p0.03), higher total
health care costs ($4250 vs. $3384), and utilization ( 1 hospitalization [8.6% vs.
4.6%],  1 emergency room visit [17.2% vs. 14.0%]) than GXR initiators (all p0.05).
After 6-months, GIR patients switched or discontinuedADHD treatmentmore than
GXR (21.3% vs. 12.8%; 73.5% vs. 53.7%, respectively (all p0.01)). Health care utili-
zation remained significantly greater for GIR patients ( 1 hospitalization [5.4% vs.
3.8%]; p0.05;  1 emergency room visit [16.0% vs. 12.5%]; p0.02), while total
health care costs ($4214 vs. $3934, p0.41) were equivalent. CONCLUSIONS: Pre-
liminary findings indicate children and adolescents may have higher rates of dis-
continuation/switching, and resource utilization when treated with GIR than GXR;
costs were not different. Further adjusted analyses are underway comparing out-
comes between the two drugs.
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OBJECTIVES: While utility improvements from depression treatments have been
studied, little research has examined utility improvements from non-pharmaco-
logical treatments in older minorities. The objective of this study was to measure
utility improvements from Beat the Blues (BTB), a non-pharmacological program
for older depressed African Americans inwhich licensed senior center social work-
ers meet with participants at home for up to 10 sessions over 4 months to assess
care needs, make referrals/linkages, provide depression education, instruct in
stress reduction techniques, and use behavioral activation to identify goals and
steps to achieve them. METHODS: Utility (EQ-5D) was measured in a single-blind
parallel group randomized clinical trial comparing BTB to wait list control. Patients
were enrolled between 2009 and 2010, were African American, age  55, had pos-
itive screen for depression (PHQ-95), English speaking, and cognitively intact.
EQ-5D was administered at T1 (baseline), T2 (4 months) and T3 (8 months). Partic-
ipants receiving control at T1 were switched to BTB at T2 and followed to T3;
participants receiving BTB at T1were switched to observation at T2 and followed to
T3 (“post-BTB”). RESULTS: EQ-5D sample sizes for the study groups were T1-T2:
BTB69; control66, and T2-T3: BTB79; post-BTB70. EQ-5D index values for BTB
versus control at T1 were 0.5701 (0.20 SD) versus 0.5705 (0.21 SD) and improved to
0.6638 (0.22 SD) versus 0.6308 (0.20 SD) at T2 (T1-T2 within group improvements
were 0.0937 and 0.0603 for BTB versus control). EQ-5D index in the post-BTB group
held from T2-T3 (slight 0.0093 within group increase). Participants switched to BTB
from control from T2-T3 showed improvement (0.0655 within group increase).
CONCLUSIONS: BTB resulted in meaningful and sustained utility improvement, in
the range of depression treatments previously studied. Findings inform discus-
sions about health gains which can be expected from non-pharmacological treat-
ments in depressed older, underserved African Americans.
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BACKGROUND: Extensive research exists estimating the effect hazardous alcohol
use on morbidity and mortality, but little research quantifies the association be-
tween alcohol consumption andutility scores in patientswith alcohol dependence.
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